About Us
CIRC was established by the National University of Singapore, Yong Loo Lin School of Medicine in 2015, and it is uniquely placed in Singapore as a dedicated molecular imaging research centre.
It is equipped with on-site capability for the preparation of PET radiopharmaceuticals in a state-of-the-art GMP-certified facility. Through the production of radiopharmaceuticals for clinical research using both short-lived and long-lived radioisotopes such as Carbon-11, Fluorine-18, Gallium-68, Lu-177, CIRC is positioned to support both academic and commercially led clinical research programs. Dedicated clinical imaging facilities area advanced modalities of Positron Emission Tomography-Computed Tomography (PET-CT) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI).
The research at CIRC focuses on disease areas relevant to Singapore and the region with the overarching objective that such research should translate into improved healthcare for the general population. In addition to manufacturing and imaging capabilities, the research group provides advanced data analysis, kinetic modelling and image reconstruction capabilities supporting disease modelling and image interpretation.
CIRC’s Mission & Vision
Mission
To provide a shared state-of-the-art national resource for translational molecular imaging research, to foster collaborations between scientists and clinicians and to support the development of human capital.
Vision
To be a leading centre for clinical molecular imaging research and to drive the development and translation of molecular imaging biomarkers and theranostics to clinical practice for improved health outcomes of the general population.
What CIRC Does?
- CIRC performs radiopharmaceutical research and development work and supports collaborations with clinicians and academic/commercial partners.
- CIRC focuses on developing multi-modal imaging and theranostic capabilities, including in the fields of neuroscience, cardiology, oncology, metabolic disorders and infectious diseases.
- Our specific aims are to develop novel technologies and biomarkers for disease, enhance the process of drug discovery and augment diagnosis and patient management capabilities in the clinic.
- To ensure proper safety and GMP practices among personnel and to support regulatory onboarding of new radiopharmaceuticals.
- Foster a culture of learning promoting the capabilities of tracer development, molecular imaging biomarkers and theranostics to improve clinical and healthcare outcomes.